These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 28823022)

  • 1. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate therapy for osteogenesis imperfecta.
    Phillipi CA; Remmington T; Steiner RD
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
    Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
    Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.
    Ying ZM; Hu B; Yan SG
    Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of osteogenesis imperfecta in adults: state of the art.
    Lafage-Proust MH; Courtois I
    Joint Bone Spine; 2019 Oct; 86(5):589-593. PubMed ID: 30742929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth of infants with osteogenesis imperfecta treated with bisphosphonate.
    Hasegawa K; Inoue M; Seino Y; Morishima T; Tanaka H
    Pediatr Int; 2009 Feb; 51(1):54-8. PubMed ID: 19371278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenesis imperfecta: diagnosis and treatment.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2014 Sep; 12(3):279-88. PubMed ID: 24964776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].
    Semler O; Land C; Schönau E
    Orthopade; 2007 Feb; 36(2):146-51. PubMed ID: 17252257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.